Inclusion Criteria:

- Patients > 18 years of age.

- Histologically documented diagnosis of one of the specified tumors, which is
malignant as well as unresectable and/or metastatic and therefore, incurable with any
conventional multimodality approach and immunohistochemical documentation of c-kit
(CD117) or PDGFR expression in the primary tumor or metastases by tumor (preferably
on a tumor sample taken within 6 week of study entry).

- At least one measurable site of disease as defined by Southwestern Oncology Group
Solid Tumor Response Criteria.

- Female patients of child-bearing potential must have negative pregnancy test.

- Signed informed consent form.

- Life expectancy >3 months.

Exclusion Criteria:

- Patient has received any other investigational agents within 28 days of the first day
of study drug dosing.

- Existence of any evidence of another malignant disease, except superficial
non-melanoma skin cancer.

- Patient has a known brain metastases.

- Patient previously received radiotherapy to >25% of the bone marrow.